Table 4.
Characteristics of the 5 patients with long-survival (median 63.3 mo)
| PT | Gender | Age | Etiology | PS | Child-Pugh | AFP > 200 ng/mL | No. of nodules | Maximum size | Macrovascular invasion | Extrahepatic spread | Diabetes | Pre-BCLC C treatments | Post-BCLC C treatments | Best response | DC | Survival (mo) | Status |
| PT3 | M | 65 | HBV | 1 | A | No | Infiltrating | Infiltrating | Yes | No | No | None | Sorafenib | CR | Yes | 79.4 | Alive |
| PT10 | M | 73 | HCV | 1 | A | No | > 3 | 18 | No | No | No | TACE, resection, sorafenib | Second line systemic agent, DSM-TACE (2) | SD | Yes | 63.3 | Alive |
| PT27 | M | 58 | HBV | 2 | B | No | 2 | 19 | No | No | No | RFA, TACE | LT | CR | Yes | 67.1 | Alive |
| PT53 | M | 63 | Alcohol | 1 | B | No | > 3 | 50 | No | No | No | None | TACE (4), TACE + RFA (1), LT | CR | Yes | 58.9 | AliVe |
| PT54 | M | 65 | HCV | 0 | A | No | Single | 40 | Yes | No | Yes | None | TARE (2) | SD | Yes | 38.1 | Alive |
HBV: Hepatitis B virus; HCV: Hepatitis C virus; PS: Performance status; BCLC: Barcelona Clinic Liver Cancer; AFP: Alphafetoprotein; TACE: Transarterial chemoembolization; RFA: Radiofrequency ablation; DSM-TACE: Degradable starch microspheres transarterial chemoembolization; LT: Liver transplant; TARE: Transarterial radioembolization; CR: Complete response; SD: Stable disease; DC: Disease control.